| Literature DB >> 30658624 |
Piotr Szumowski1, Saeid Abdelrazek2, Łukasz Żukowski2, Małgorzata Mojsak2, Monika Sykała2, Katarzyna Siewko3, Katarzyna Maliszewska3, Anna Popławska-Kita3, Janusz Myśliwiec2.
Abstract
BACKGROUND: The most frequently used methods of assessing Graves' orbithopathy (GO) include: Clinical Activity Score (CAS), ultrasonography (USG), computed tomography (CT), and magnetic resonance imaging (MRI). There exists another, slightly forgotten, imaging method: single-photon emission computed tomography (SPECT) with the use of diethylenetriaminepentaacetic acid tagged with 99mTc (99mTc-DTPA). These days it is possible to conduct a SPECT examination fused with a CT scan (SPECT/CT), which increases the diagnostic value of the investigation. The aim of this paper is to evaluate the usefulness of 99mTc-DTPA SPECT/CT in diagnosing Graves orbitopathy, as compared with other methods.Entities:
Keywords: 99mTc-DTPA; Graves’ orbitopathy; MRI; SPECT/CT
Mesh:
Substances:
Year: 2019 PMID: 30658624 PMCID: PMC6339418 DOI: 10.1186/s12902-019-0340-0
Source DB: PubMed Journal: BMC Endocr Disord ISSN: 1472-6823 Impact factor: 2.763
Fig. 199mTc-DTPA SPET/CT scintigraphy of the orbital cavity in coronal planes. All the rectus muscles of the eye are thickened: a) with increased accumulation of 99mTc-DTPA only in the medial and superior muscles of the right eye, which is indicative of active GO in the medial and superior muscles. b without increased accumulation of 99mTc-DTPA, which is indicative of non-active GO. The physiological 99mTc-DTPA uptake of nasal mucosa is visible at both cases. Abbreviations: MRI = magnetic resonance imaging; SPECT-CT = fused single photon emission computed tomography with computed tomography; GO = Graves’ orbitopathy; 99mTc-DTPA = diethylenetriaminepentaacetic acid tagged with 99mTc
Results of active (+) and non-active (−) forms of GO in 23 patients after CAS, MRI, and SPECT/CT
| GO patients | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | |
| CAS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MRI |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SPECT/CT |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Abbreviations: +, positive result (active GO); −, negative result (non-active GO); CAS clinical activity score, MRI magnetic resonance imaging, SPECT-CT fused single photon emission computed tomography with computed tomography, GO Graves’ orbitopathy
Correlation between real occurrence of active or non-active GO and result of CAS (contingency table)
| Active GO | Non-active GO | Total | |
|---|---|---|---|
| Positive result | 12 | 4 | 16 |
| Negative result | 2 | 5 | 7 |
| Total | 14 | 9 | 23 |
GO Graves’ orbitopathy, CAS clinical activity score
Correlation between real occurrence of active or non-active GO and result of MRI (contingency table)
| Active GO | Non-active GO | Total | |
|---|---|---|---|
| Positive result | 13 | 2 | 15 |
| Negative result | 1 | 7 | 8 |
| Total | 14 | 9 | 23 |
GO Graves’ orbitopathy, MRI Magnetic resonance imaging
Correlation between real occurrence of active or non-active GO and result of SPECT/CT (contingency table)
| Active GO | Non-active GO | Total | |
|---|---|---|---|
| Positive result | 13 | 1 | 14 |
| Negative result | 1 | 8 | 9 |
| Total | 14 | 9 | 23 |
GO Graves’ orbitopathy, SPECT/CT fused single photon emission computed tomography with computed tomography
Assessment parameters for diagnostic methods CAS, MRI and SPECT/CT in detecting active GO
| CAS | MRI | SPECT/CT |
| |
|---|---|---|---|---|
| Sensitivity | 0.86 | 0.93 | 0.93 | 0.048a, b/c |
| −95% CI | 0.51 | 0.81 | 0.83 | |
| + 95% CI | 0.92 | 0.98 | 0.99 | |
| Specificity | 0.56 | 0.78 | 0.89 | 0.039a,b,c |
| −95% CI | 0.29 | 0.55 | 0.58 | |
| + 95% CI | 0.56 | 0.89 | 0.99 | |
| PPV | 0.75 | 0.87 | 0.93 | 0.031a,b,c |
| −95% CI | 0.47 | 0.61 | 0.73 | |
| + 95% CI | 0.81 | 0.97 | 0.98 | |
| NPV | 0.71 | 0.88 | 0.89 | 0.049a,b,c |
| −95% CI | 0.54 | 0.66 | 0.77 | |
| + 95% CI | 0.76 | 0.95 | 0.98 | |
| ACC | 0.74 | 0.87 | 0.91 | 0.050a,b,c |
| −95% CI | 0.63 | 0.58 | 0.92 | |
| + 95% CI | 0.88 | 0.94 | 0.98 |
PPV positive predictive value, NPV, negative positive predictive value, ACC accuracy, other abbreviations, see Table 1
a, b, c - statistically significant difference between parameters of three examinations (CAS, MRI, and SPECT/CT)
a, b/c - statistically significant difference between parameters of CAS and (MRI or SPECT/CT), lack of statistically significant difference between MRI and SPECT/CT
Impact of active GO on average total thickness of muscles in orbital cavity and occurrence of exophthalmos
| Average total thickness of oculomotor muscles in one eye | Exophthalmos | ||
|---|---|---|---|
| Active GO (No 14) | 40 mm +/−6 mm | 23 +/− 5.0 mm | NS |
| Non-active GO (No 9) | 39 mm +/−7 mm | 23 +/− 4.5 mm | NS |
GO, Graves’ orbitopathy; M, Mean; SD, standard deviation; NS, Not statistically significant; No, Number